Speak to the pharma team
01628 581 240
Speak to the healthcare team
01225 336 335
Speak to the clinical team
01628 581 240
Speak to the contract team
01225 336 335
Speak to us about Master Vendor
01225 336 335
Or send your enquiry via email and the best person to help will be in touch.
solutions@starmedical.co.uk
Samantha Wise
01628 581 240
Receive updates
As of October 2007 Cambridge Antibody Technology (or CAT), a biopharmaceutical company, was incorporated by MedImmune, a biotechnology company wholly owned by AstraZeneca plc. CAT, with their early development experience, and MedImmune, bringing mature development experience and state-of-the-art manufacturing facilities, were acquired by AstraZeneca as part of their long-term strategic investment in novel biological therapeutics.
Now known as MedImmune, the company are still based near Cambridge. They develop human monoclonal antibody therapeutics, complimenting AstraZeneca's ambitions to develop three technological approaches: small molecules, biologics and vaccines.
Abbott's Humira, used in the treatment of rheumatoid arthritis, was the first CAT-derived antibody to be approved for marketing and the first product originating from the UK biotechnology industry to achieve blockbuster status, with US sales of over $2 billion. This product is now marketed in more than 50 different countries. Several more of their human monoclonal antibodies have been licensed and are at various stages of clinical trial with partners such as Abbott and Wyeth. These include:
CAT-8015
CAT-354
GC-1008
CAM-3001
ABT-874
LymphoStat-BTM
HGS-ETR1
HGS-ETR2
ABthraxTM
MYO-029
CAT-213
“I’m really grateful to you for giving up your time over the weekend to give me inspiration. You have been absolutely outstanding.”
“It’s a refreshing change where the recruitment consultant is as passionate about the applicant as the customer hiring.”
